Related Experiment Video
Updated: Aug 2, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen
Qingming Wang1, Feng He2, Wenfeng He3
1Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Background:
Chimeric antigen receptor T cells (CAR-T) against B-cell maturation antigen (BCMA) has been used to treat multiple myeloma (MM). CAR-T cells co-expressing a truncated human EGFR (tEGFR) has been proposed for in vivo cell ablation.
Methods:
We designed and tested a novel anti-BCMA CAR. We transduced T cells with retroviral vectors encoding CAR and tEGFR. The anti-BCMA-CAR-transduced T cells were evaluated for the functions including cytokine production, proliferation, cytotoxicity, and in vivo tumor eradication of BCMA. Cetuximab was used for in vivo cell ablation.
Results:
The CAR-T cells could specifically recognize BCMA, and anti-BCMA CAR-T cells could exhibit interferon-γ and cytotoxicity specifically produced by BCMA and eradicate tumor in vivo. Cetuximab could mediate antibody-dependent cellular cytotoxicity and in vivo elimination.
Conclusions:
We confirm that BCMA is a suitable target for CAR- T cells and tEGFR is a effective tool for cellular ablation.
